Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in Relapsed/Refractory Multiple Myeloma With BRAF Mutation
NCT02115035Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Jul 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in multiple myeloma (MM), sponsored by University of Arkansas. Planned start Jul 2014; status: withdrawn.
02
Drugs
vemurafenib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02115035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115035.